



COPY OF P. AS
ORIGINALLY FILED

RECEIVED
AUG 19 2002

TECH CENTER 1600/290

AMENDMENT TRANSMITTAL LETTER			DOCKET NUMBER: P-NI 4577	
SERIAL NO: 09/768,020	FILING DATE: January 23, 2001	EXAMINER: P. Paras	GROUP ART UNIT: 1632	
INVENTION: METHOD FOR FUNCTIONAL MAPPING OF AN ALZHEIMER'S DISEASE GENE NETWORK AND FOR IDENTIFYING THERAPEUTIC AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE				

TO COMMISSIONER FOR PATENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on August 5, 2002.

By: Astrid R. Spain
Astrid R. Spain, Reg. No. 47,956

August 5, 2002
Date of Signature

Transmitted herewith is a Response to Restriction Requirement mailed June 5, 2002, in the above-identified application.

- ☐ Small Entity status of this application has been established under 37 CFR 1.27.
- ☒ Petition for One-Month Extension of Time is enclosed (in duplicate).
- ☐ Terminal Disclaimer with fee under 37 C.F.R. 1.20(d) is enclosed.
- ☒ No additional claims fee is required.
- ☐ An additional claims fee is required and has been calculated as shown below:

CLAIMS AS AMENDED

	NUMBER AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE			FEE	
							SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	37	-	37	-	0	x	\$9	\$18	=	\$	\$0.00
INDEPENDENT CLAIMS	6	-	6	-	0	x	\$42	\$84	=	\$	\$0.00
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			<input type="checkbox"/> YES		<input checked="" type="checkbox"/> NO		\$140	\$280	=	\$	\$0.00
							TOTAL ADDITIONAL FEE			\$	\$0.00

- * If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.
- ** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.
- *** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

Inventors: Greenspan and Edelman
Serial No.: 09/768,020
Filed: January 23, 2001
Page 2


 Please charge my Deposit Account No. 03-0370 the amount of
\$. A duplicate copy of this sheet is enclosed.

 X A check in the amount of \$110.00 is enclosed, which covers
the fee for a one-month extension of time.

 X The Commissioner is hereby authorized to charge payment of
any fees associated with this communication or credit any
overpayment to Deposit Account No. 03-0370. A duplicate
copy of this sheet is enclosed.

 X The Commissioner is hereby authorized to charge to Deposit
Account No. 03-0370 any fees under 37 CFR 1.17 which may be
required under 37 CFR 1.136(a)(3) for an extension of time
in any concurrent or future reply requiring a petition for
extension of time. A duplicate copy of this sheet is
enclosed.

Respectfully submitted,



Astrid R. Spain
Registration No. 47,956
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
858-535-9001
USPTO CUSTOMER NO. 23601

Inventors: Greenspan and Edelman
Serial No.: 09/768,020
Filed: January 23, 2001
Page 2

X The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted

By: Andrea L. Gashler
Andrea L. Gashler
Reg. No. 41,029

CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
Telephone: (858) 535-9001
Facsimile: (858) 535-8949
USPTO CUSTOMER NO. 23601



RECEIVED
AUG 19 2002
#18
DIA
8/23/02

PATENT

Our Docket: P-NI TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Greenspan and Edelman

Serial No: 09/768,020

Filed: January 23, 2001

For: METHOD FOR FUNCTIONAL MAPPING)
OF AN ALZHEIMER'S DISEASE GENE)
NETWORK AND FOR IDENTIFYING)
THERAPEUTIC AGENTS FOR THE)
TREATMENT OF ALZHEIMER'S)
DISEASE)

Group Art Unit: 1632

Examiner: P. Paras

I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail in an
envelope addressed to: Commissioner for Patents,
Washington, D.C. 20231, on August 5, 2002.

By Astrid R. Spain
Astrid R. Spain, Reg. No. 47,956

August 5, 2002
Date of Signature

Commissioner for Patents
Washington, D.C. 20231

COPY OF PAPERS
ORIGINALLY FILED

RESPONSE TO OFFICE ACTION

Responsive to the Office Action mailed June 5, 2002,
Applicants respectfully request consideration of the following
remarks.

Claims 1-37 are pending. The Examiner alleges that the
claims are directed to eighty-two distinct and independent
inventions as follows:

Group I: Claims 1 through 21, directed to a
method of mapping a network of
functional gene interactions relating to
Alzheimer's disease, classified in the
classes 800 and 435, subclasses 13, 22
and 455;

Inventors: Greenspan and Edelman
Serial No.: 09/768,020
Filed: January 23, 2001
Page 2

Group II: Claims 22 through 29, directed to a method for identifying a therapeutic agent for treating Alzheimer's disease, classified in class 800, subclass 3;

Groups III-LXV: Claims 30 through 33 each group directed to the nucleotide sequence set forth as SEQ ID NOS: 1 through 63, respectively, classified in class 536, subclass 23.1; and

Groups LXVI-LXXXII: Claims 30 through 33, each group directed to the nucleotide sequence set forth as SEQ ID NOS: 64 through 80, respectively, classified in class 536, subclass 23.1.

Election of one of the inventions is required under 35 U.S.C. § 121. Although the restriction requirement is traversed for the reasons discussed below, Applicants elect the claims set forth in Group II, claims 22-29, for examination.

Applicants respectfully submit that examination of the claims of Group II together with the claims of Group I, claims 1-21, would not present an undue burden upon the Examiner. Applicants submit that a thorough examination of the claims of Group II, which are directed to a method for identifying a therapeutic agent for treating Alzheimer's disease, will include

Inventors: Greenspan and Edelman
Serial No.: 09/768,020
Filed: January 23, 2001
Page 3

an examination of the claims of Group I, which are directed to directed to a method of mapping a network of functional gene interactions relating to Alzheimer's disease. In particular, the method of Group II for identifying a therapeutic agent for treating Alzheimer's disease is practiced with parent strains that are identified via the method of Group I and produce test progeny having an altered phenotype relative to at least one sibling control, thereby localizing a gene that is a member of an Alzheimer's disease genetic network to one of a series of genetic variations. Therefore, a thorough examination of the claims of Group II will necessarily encompass examination of subject matter relevant to the claims of Group I, with limited additional subject matter required for the examination of these claims. For these reasons, Applicants respectfully submit that examining these claims together would not present an undue burden upon the Examiner and request examination of the claims of Group II together with the claims of Group I.


In view of the above remarks, Applicants request that claims 22-29, of Group II be examined and further request that the Examiner reconsider the Restriction Requirement and examine the subject matter relating to Group I, claims 1-21, together with the elected subject matter relating to Group II.

Inventors: Greenspan and Edelman
Serial No.: 09/768,020
Filed: January 23, 2001
Page 4

The Examiner is invited to call the undersigned attorney or
Cathryn Campbell if there are any questions.

Respectfully submitted,

August 5, 2002
Date


Astrid R. Spain
Registration No. 47,956
Telephone No. (858) 535-9001
Facsimile No. (858) 535-8949

CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
USPTO CUSTOMER NO. 23601